FDA Warning on Hot Flash Drug: Fezolinetant Poses Liver Injury Risks
Thursday, 12 September 2024, 12:57
FDA Issues Safety Alert on Fezolinetant
In a significant announcement, the FDA has released warnings regarding fezolinetant (Veozah), a medication aimed at alleviating moderate to severe hot flashes due to menopause. While marketed as a hormone-free option, the agency highlights serious concerns regarding potential liver injuries associated with its use.
Key Safety Information
- Fezolinetant is administered in pill form, offering women a non-hormonal alternative.
- Patients should monitor for symptoms of liver damage, including jaundice and abdominal pain.
- Discussing thorough medical history with healthcare providers is vital before starting this medication.
Recommendations for Patients
- Evaluate the risk vs. benefit with your healthcare provider.
- Report any unusual symptoms immediately.
- Stay informed about ongoing updates from the FDA regarding fezolinetant.
This article was prepared using information from open sources in accordance with the principles of Ethical Policy. The editorial team is not responsible for absolute accuracy, as it relies on data from the sources referenced.